Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP.
The dopamine (DA) content of the mouse striatum thirty days after treatment with MPTP is significantly reduced. GM1 ganglioside administration during the thirty day period results in a partial restoration of the striatal DA content.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D005677:G(M1) Ganglioside / Q000494:pharmacology*; D008297:Male; D051379:Mice; D011725:Pyridines / Q000494:pharmacology*; D013997:Time Factors
D011725:Pyridines; D005677:G(M1) Ganglioside; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine